Integrated Advisors Network LLC Has $8.17 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

Integrated Advisors Network LLC lifted its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 299.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,628 shares of the company’s stock after acquiring an additional 67,199 shares during the period. Integrated Advisors Network LLC’s holdings in Merck & Co., Inc. were worth $8,171,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. TFO TDC LLC acquired a new stake in Merck & Co., Inc. during the second quarter worth $31,000. Moisand Fitzgerald Tamayo LLC boosted its stake in Merck & Co., Inc. by 69.9% during the second quarter. Moisand Fitzgerald Tamayo LLC now owns 367 shares of the company’s stock worth $33,000 after buying an additional 151 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE acquired a new stake in Merck & Co., Inc. during the second quarter worth $47,000. GW&K Investment Management LLC boosted its stake in Merck & Co., Inc. by 85.8% during the first quarter. GW&K Investment Management LLC now owns 561 shares of the company’s stock worth $46,000 after buying an additional 259 shares in the last quarter. Finally, Steward Financial Group LLC boosted its stake in Merck & Co., Inc. by 26.7% during the second quarter. Steward Financial Group LLC now owns 727 shares of the company’s stock worth $66,000 after buying an additional 153 shares in the last quarter. Institutional investors and hedge funds own 73.33% of the company’s stock.

Analysts Set New Price Targets

MRK has been the topic of a number of recent research reports. StockNews.com assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Credit Suisse Group assumed coverage on Merck & Co., Inc. in a report on Thursday, November 17th. They set an “outperform” rating and a $120.00 price objective for the company. Truist Financial lifted their price objective on Merck & Co., Inc. from $103.00 to $106.00 and gave the company a “buy” rating in a report on Friday, October 28th. Citigroup lifted their price objective on Merck & Co., Inc. to $105.00 in a report on Tuesday, November 15th. Finally, Erste Group Bank raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Thursday, August 25th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $106.00.

Insiders Place Their Bets

In other Merck & Co., Inc. news, insider Johannes Jacobus Oosthuizen sold 1,795 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $103.21, for a total transaction of $185,261.95. Following the completion of the sale, the insider now directly owns 16,731 shares of the company’s stock, valued at approximately $1,726,806.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Robert M. Davis sold 167,613 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $102.44, for a total transaction of $17,170,275.72. Following the completion of the transaction, the chief executive officer now directly owns 247,593 shares in the company, valued at approximately $25,363,426.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Johannes Jacobus Oosthuizen sold 1,795 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $103.21, for a total value of $185,261.95. Following the transaction, the insider now owns 16,731 shares of the company’s stock, valued at $1,726,806.51. The disclosure for this sale can be found here. In the last three months, insiders sold 1,081,815 shares of company stock valued at $108,575,433. 0.29% of the stock is currently owned by insiders.

Merck & Co., Inc. Trading Down 0.1 %

NYSE:MRK traded down $0.08 on Thursday, hitting $106.82. 5,750,005 shares of the stock were exchanged, compared to its average volume of 9,894,878. The stock has a market capitalization of $270.83 billion, a price-to-earnings ratio of 17.77, a P/E/G ratio of 1.42 and a beta of 0.38. Merck & Co., Inc. has a 52 week low of $71.50 and a 52 week high of $107.30. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 1.46. The company’s 50-day moving average price is $94.50 and its 200 day moving average price is $91.59.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its quarterly earnings data on Thursday, October 27th. The company reported $1.85 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.18. The firm had revenue of $14.96 billion during the quarter, compared to analysts’ expectations of $14.05 billion. Merck & Co., Inc. had a return on equity of 46.57% and a net margin of 25.88%. The company’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.75 EPS. On average, equities research analysts forecast that Merck & Co., Inc. will post 7.38 earnings per share for the current year.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.